These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 22826745)
1. Estimating the cost to rural ambulating HIV/AIDS patients on highly active antiretroviral therapy (HAART) in rural Ghana: a pilot study. Apanga S; Punguyire D; Adjei G Pan Afr Med J; 2012; 12():21. PubMed ID: 22826745 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of highly active antiretroviral therapy in South Africa. Badri M; Maartens G; Mandalia S; Bekker LG; Penrod JR; Platt RW; Wood R; Beck EJ PLoS Med; 2006 Jan; 3(1):e4. PubMed ID: 16318413 [TBL] [Abstract][Full Text] [Related]
3. Medical resource utilization and cost of HIV-related care in the highly active antiretroviral therapy era at a University Clinic in Sweden. Ghatnekar O; Hjortsberg C; Gisslén M; Lindbäck S; Löthgren M Pharmacoeconomics; 2010; 28 Suppl 1():49-57. PubMed ID: 21182343 [TBL] [Abstract][Full Text] [Related]
4. The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001. Krentz HB; Auld MC; Gill MJ; CMAJ; 2003 Jul; 169(2):106-10. PubMed ID: 12874156 [TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001. Beck EJ; Mandalia S; Gaudreault M; Brewer C; Zowall H; Gilmore N; Klein MB; Lalonde R; Piché A; Hankins CA AIDS; 2004 Dec; 18(18):2411-8. PubMed ID: 15622317 [TBL] [Abstract][Full Text] [Related]
6. Expenditures for the care of HIV-infected patients in rural areas in China's antiretroviral therapy programs. Zhou F; Kominski GF; Qian HZ; Wang J; Duan S; Guo Z; Zhao X BMC Med; 2011 Jan; 9():6. PubMed ID: 21241494 [TBL] [Abstract][Full Text] [Related]
7. The direct costs of HIV/AIDS care. Levy AR; James D; Johnston KM; Hogg RS; Harrigan PR; Harrigan BP; Sobolev B; Montaner JS Lancet Infect Dis; 2006 Mar; 6(3):171-7. PubMed ID: 16500598 [TBL] [Abstract][Full Text] [Related]
8. Financial burden of health care for HIV/AIDS patients in Vietnam. Tran BX; Duong AT; Nguyen LT; Hwang J; Nguyen BT; Nguyen QT; Nong VM; Vu PX; Ohinmaa A Trop Med Int Health; 2013 Feb; 18(2):212-8. PubMed ID: 23210600 [TBL] [Abstract][Full Text] [Related]
9. Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmaco-economic implications in a population-based setting. Torti C; Casari S; Palvarini L; Quiros-Roldan E; Moretti F; Leone L; Patroni A; Castelli F; Ripamonti D; Tramarin A; Carosi G Health Policy; 2003 Sep; 65(3):261-7. PubMed ID: 12941493 [TBL] [Abstract][Full Text] [Related]
10. The societal burden of HIV/AIDS in Northern Italy: an analysis of costs and quality of life. Hubben GA; Bishai D; Pechlivanoglou P; Cattelan AM; Grisetti R; Facchin C; Compostella FA; Bos JM; Postma MJ; Tramarin A AIDS Care; 2008 Apr; 20(4):449-55. PubMed ID: 18449822 [TBL] [Abstract][Full Text] [Related]
11. Brief communication: economic comparison of opportunistic infection management with antiretroviral treatment in people living with HIV/AIDS presenting at an NGO clinic in Bangalore, India. John KR; Rajagopalan N; Madhuri KV MedGenMed; 2006 Nov; 8(4):24. PubMed ID: 17415293 [TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV. Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of highly active antiretroviral therapy for HIV infection in Taiwan. Fang CT; Chang YY; Hsu HM; Twu SJ; Chen KT; Chen MY; Huang LY; Hwang JS; Wang JD J Formos Med Assoc; 2007 Aug; 106(8):631-40. PubMed ID: 17711796 [TBL] [Abstract][Full Text] [Related]
14. Pediatric HIV costs across three treatment eras from 1986 to 2007. Wilson LS; Basu R; Christenson M; Hensic L; Paoli C; Wara D; Moskowitz JT Pediatrics; 2010 Sep; 126(3):e541-9. PubMed ID: 20696721 [TBL] [Abstract][Full Text] [Related]
15. Long-term impact of highly active antiretroviral therapy on HIV-related health care costs. Keiser P; Nassar N; Kvanli MB; Turner D; Smith JW; Skiest D J Acquir Immune Defic Syndr; 2001 May; 27(1):14-9. PubMed ID: 11404515 [TBL] [Abstract][Full Text] [Related]
16. Predicting direct costs of HIV care during the first year of darunavir-based highly active antiretroviral therapy using CD4 cell counts: evidence from POWER. Hill AM; Gebo K; Hemmett L; Löthgren M; Allegri G; Smets E Pharmacoeconomics; 2010; 28 Suppl 1():169-81. PubMed ID: 21182350 [TBL] [Abstract][Full Text] [Related]
17. The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda. Marseille E; Kahn JG; Pitter C; Bunnell R; Epalatai W; Jawe E; Were W; Mermin J Appl Health Econ Health Policy; 2009; 7(4):229-43. PubMed ID: 19905037 [TBL] [Abstract][Full Text] [Related]
18. A comparative analysis of outpatient costs in HIV treatment programs. Sarti FM; Nishijima M; Campino AC; Cyrillo DC Rev Assoc Med Bras (1992); 2012; 58(5):561-7. PubMed ID: 23090227 [TBL] [Abstract][Full Text] [Related]
19. Costs of medical services for patients with HIV/AIDS in Khon Kaen, Thailand. Kitajima T; Kobayashi Y; Chaipah W; Sato H; Chadbunchachai W; Thuennadee R AIDS; 2003 Nov; 17(16):2375-81. PubMed ID: 14571190 [TBL] [Abstract][Full Text] [Related]
20. Costs of care provided in a university hospital for children exposed to or infected with the HIV/AIDS. Marques HH; Couttolenc BF; Latorre Mdo R; Aquino MZ; Aveiro MI; Pluciennik AM Cad Saude Publica; 2007; 23 Suppl 3():S402-13. PubMed ID: 17992346 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]